Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

NCT03170180 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03170180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03170180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2017
Completion date
December 28, 2021
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stomach neoplasms